Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products
Novo Nordisk has filed a federal lawsuit accusing telehealth company Hims & Hers Health of infringing its semaglutide patent by marketing and selling compounded weight loss drugs. The case, filed in the U.S. District Court for the District of Delaware, challenges whether Hims’ compounded semaglutide products unlawfully use technology protected... Read More »